Cross-border clinical-practice-variation-based development of COvid-19 DAta-driven consensus treatment guidelines and the creation of an Euregio COVID-19 data Platform to anticipate a new wave.

Programme 2014 - 2020 INTERREG V-A Belgium - Germany - The Netherlands Euregio Meuse-Rhin / Euregio Maas-Rijn / Euregio Maas-Rhein

Date of latest update: 2022-07-11

Description

Description (EN):

Euregio, with a high population density, intense cross-border passage and only an estimated 5-10% of inhabitants that ran through infection during this first pandemic wave, is likely struck hard again in a second COVID-19 wave. If so, we aim to provide all available care, including admission to Intensive Care Unit (ICU), to those patients that will benefit and withhold care for those who do not, while focussing on supportive care for both them and their family. We have to learn lessons now to guide decisions on future care far better. The cross-border perspective in learning lessons is likely to unravel additional ones. As inhabitants of Euregio are alike, differences in outcomes are also driven by system factors. Within Euregio, healthcare systems, hospital infrastructure, admission criteria and treatment choices vary considerably. Notably, availability of ICU beds in the Netherlands is 6.4, compared to 29.2 and 15.9 per 100.000 inhabitants for Germany and Belgium, resp. Scarce ICU resources should be optimally used during a pandemic, in agreement with regular care, which inevitably affects physician decisions. We learned a great heterogeneity in disease course of COVID-19 infection. This heterogeneity is amplified since no specific treatment for COVID-19 exists (experimental off-label therapies e.g. hydroxychloroquine, antiviral drugs, steroids, interleukin receptor blockers were used variably between centres and countries). With a major focus on cross-border differences, a solid evaluation on heterogeneity that describes baseline demographics, evaluates disease courses over time, addresses sex differences, investigates relationships with outcome and evaluates treatment differences will show unique results of effects of different choices/settings (including health care systems). A cross-border prospectively collected ICU COVID-19 cohort does not exist, but is urgently needed. A large well-characterised Euregio COVID-19 cohort that incorporates the "natural" variation between countries can reveal best practice throughout our region to benefit future COVID-19 patients, at least, throughout our region and countries. Conversely, while taking different settings (including health care systems) into account, Euregio data can be used to predict outcome. Established prediction scores for general ICU populations appear inappropriate for COVID-19 population, which differ clinically. Fortunately, many COVID-19 prediction scores become available. Euregio data has major advantages to investigate their external validity cross-border, and, particularly, could establish whether certain scores perform better in one hospital or country over the other. Development of new, or adaptation of existing models for Euregio specifically will help to inform physicians better. Aims: (1) study heterogeneity differences in ICU patient populations, (2) improve clinical decisions guidelines, and (3) build IT-infrastructure for secure and efficient data-exchange and analysis. Obj 1. We intend to connect isolated efforts into a single Euregio cohort network and pioneer new concepts of patient characterisation, machine learning and outcome evaluation (Table 1). Network partners will be granted access to the common data model, and algorithms will be made available to the entire cohort network, boosting collaborative research efforts using a common data platform. To start, the euregionally prespecified, and prospectively collected data on COVID-19 will identify differences between countries. First, description of data combined with advanced statistical modelling with outcome data will unravel heterogeneity and reveal results on best practices throughout our region. Next, we will validate existing prediction models, adapting them for Euregio and develop new prediction models with outcome. Obj 2. Review current guidelines and adapt these using data-driven results to inform physicians on COVID-19 patients. Results from analyses that use "natural" variation throughout Euregio and reveal best practice will form a basis for guideline refinement. This will guide physicians to admit patients to an ICU or not and to continue life-sustaining treatment or forgo life-sustaining support if considered futile in a more uniform way throughout the region. Obj 3. The overarching ambition is to build a growing data platform that will host the dataset, making shared access possible, that respects best technical and regulatory practices, to benefit target groups (Table 2). In addition to enabling research, this infrastructure will create a dashboard sharing near-real-time ICU data on patient admissions and Euregio bed availability. By detecting effects on ICU capacity and clinical course earlier, hospitals will have more time to collaborate, reorganise and prepare for the upcoming wave.

Website: http://www.interregemr.eu/

Thematic information

Health and social services

Specific Objective: Increase connections and synergies between enterprises, R&D centres and higher education

Thematic Objective: (01) strengthening research, technological development and innovation by:

Investment Priority:

(01b) promoting business investment in R&I, developing links and synergies between enterprises, research and development centres and the higher education sector, in particular promoting investment in product and service development, technology transfer, social innovation, eco-innovation, public service applications, demand stimulation, networking, clusters and open innovation through smart specialisation, and supporting technological and applied research, pilot lines, early product validation actions, advanced manufacturing capabilities and first production, in particular in key enabling technologies and diffusion of general purpose technologies

Partners (5)

Lead Partner: Ziekenhuis Oost-Limburg

Department: Intensive Care / Future Health

Address: Schiepse Bos 6, 3600 Genk, Belgium

Legal status: public

Website: http://www.zol.be

Total budget: EUR 276 869.90

ERDF budget: EUR 249 182.91

Jessa Ziekenhuis

Name: Jessa Ziekenhuis

Department: Intensive Care

Address: Stadsomvaart 11, 3500 Hasselt, Belgium

Legal status: public

Website: http://www.jessazh.be

Total budget: EUR 130 992.27

ERDF budget: EUR 117 893.04

Maastricht UMC+

Name: Maastricht UMC+

Department: Intensive Care

Address: P. Debyelaan 25, 6229 HX Maastricht, Netherlands

Legal status: public

Website: http://www.mumc.nl

Total budget: EUR 245 382.06

ERDF budget: EUR 220 843.85

Universitätsklinikum der RWTH Aachen

Name: Universitätsklinikum der RWTH Aachen

Department: Anesthesiology

Address: Pauwelsstraße 30, 52074 Aachen, Germany

Legal status: public

Website: http://www.ukaachen.de

Total budget: EUR 125 060.32

ERDF budget: EUR 112 554.29

Groupe santé CHC

Name: Groupe santé CHC

Department: Intensive Care

Address: bd Patience et Beaujonc 9, 4000 Liège, Belgium

Legal status: public

Website: http://www.chc.be

Total budget: EUR 117 424.64

ERDF budget: EUR 105 682.18

Partners map

Lead partner

Project partner

Summary

Project name (EN): Cross-border clinical-practice-variation-based development of COvid-19 DAta-driven consensus treatment guidelines and the creation of an Euregio COVID-19 data Platform to anticipate a new wave.

Project acronym: CoDaP

Project start date: 2020-07-01

Project end date: 2021-06-30

Project status: closed

Total budget/expenditure: EUR 895 729.19

Total EU funding (amount): EUR 806 156.27

Co-financing sources:

ERDF: Amount, EUR 806 156.27.

Information regarding the data in keep.eu on the programme financing this project

Financing programme

2014 - 2020 INTERREG V-A Belgium - Germany - The Netherlands Euregio Meuse-Rhin / Euregio Maas-Rijn / Euregio Maas-Rhein

Last month that data in keep.eu was retrieved from the Programme's website or received from the Programme

2024-02-28

No. of projects in keep.eu / Total no. of projects (% of projects in keep.eu)

65 / 65 (100%)

No. of project partnerships in keep.eu / Total no. of project partnerships (% of project partnerships in keep.eu)

500 / 514 (97.28%)

Notes on the data

Information provided by the Programme. Data of two projects (EMfloodResilience and MARHETAK) was retrieved by Interact from the programme´s website on the 2024-02-28. Regarding partners only data only main partners is available. Achievements were retrieved by Interact from the Programme website (http://www.interregemr.eu/), or a website directly linked from it, on 2021-11-04, 2023-01-10 and 2024-03-07. Fields project name (from 14 projects) translated from French, German, and Dutch into English using the European Commission's eTranslation machine translation service.

The projects which fields include an eTranslation English text are the ones with the following acronyms: EMRLingua, EMRWINE, euPrevent SNA, euPrevent-SFC, FUNFORLAB, GAR 4.0, GYM-Generate Your Muscle, Healthy Aging, i2-CoRT, IDZ-UDZ, MOBI, RANDO-M, Terra Mosana and Wohnmonitor EMR.

The financial data featured in keep.eu for this programme, it's projects and its partners is not exact and should be taken as a reference only.

Languages

Contact Form

Cross-border clinical-practice-variation-based development of COvid-19 DAta-driven consensus treatment guidelines and the creation of an Euregio COVID-19 data Platform to anticipate a new wave.

Description

Thematic information

Partners (5)

Partners map

Summary

Information regarding the data in keep.eu on the programme financing this project

Disclaimer